Summary statistics - quantitative results

EQA round: KD4/26 - Glycated Haemoglobin

Deadline: 30.10.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average
SD = standard deviation
CV = coefficient of variation
N_{tot} = total number of the results
N_{out} = number of the results removed before calculation
AV = assigned value
CVP = consensus of all participants
U_{AV} = expanded uncertainty of the assigned value (k = 2)
D_{max} = acceptable difference
LL = lower limit
UL = upper limit
N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
(220) **Haemoglobin A_{1c}**	[mmol/mol]				192								192	186	97
Sample A		61,5	2,4	3,9	192		CVP	61,5	0,42	asym.	55	68	192	189	98
(14) Bio-Rad		63,1	2,2	3,6	39	0							39		
(25) TOSOH		63,1	1,4	2,2	44	0							44		
(34) Sebia		59,9	0,94	1,6	20	0							20		
(60) Roche		60,4	2	3,3	20	0							20		
(150) Arkray		60,7	1,6	2,6	56	0							56		
Other					13	0							13		
							4x 1, 3x 46, 2x 58, 2x 162, 1x 177, 1x 999								
Sample B		44,7	1,8	4,1	192		CVP	44,7	0,32	asym.	40	50	192	188	98
(14) Bio-Rad		45	2,3	5	39	0							39		
(25) TOSOH		45,7	1,3	2,8	44	0							44		
(34) Sebia		43,5	0,83	1,9	20	0							20		
(60) Roche		44,8	2,2	4,9	20	0							20		
(150) Arkray		44,3	1,2	2,8	56	0							56		
Other					13	0							13		
							4x 1, 3x 46, 2x 58, 2x 162, 1x 177, 1x 999								